Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

FDA Approves LaserSight's LSX for Myopic Astigmatism

Facebook Twitter LinkedIn Email Comments
WINTER PARK, Fla., Oct. 3 -- LaserSight Inc. said that the FDA has approved its LaserScan LSX precision microspot scanning excimer laser system for the LASIK treatment of myopia (nearsightedness) with and without astigmatism. The approval is for a range of treatment of refractive errors up to -6.00 diopters manifest refraction spherical equivalent (MRSE) with or without a refractive astigmatism up to 4.5 diopters of cylinder.

The range of spherical equivalent approved for treatment is reported to address approximately 85 percent of the myopic patients currently applying for refractive surgery. In November 1999, the Company's LaserScan LSX was approved for treatment by photorefractive keratectomy of nearsightedness up to -6 diopters; however refractive surgeons in the US are permitted to treat patients for nearsightedness up to -10 diopters.
Oct 2001
News & Featureslasers

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.